First to Market The Clarity RMS system represents the first commercially available solution for continuous urine flow monitoring with automated data transmission to EMR and intelligent alarms, creating a durable competitive moat in ICU renal diagnostics. Target early adopters in large academic medical centers and leverage its unique real-time capability to build clinical case studies and ROI demonstrations.

Economic ROI AKI affects a large share of ICU patients and is linked to longer stays and higher costs. Clarity RMS offers a real-time, labor-reducing workflow that can shorten ICU stays and lower avoidable costs, creating a strong CFO-facing ROI story. Propose pilots and an ROI model to hospital networks to accelerate adoption.

Global Expansion The company already has distribution agreements in Taiwan, China, and Israel and Europe potential through Fresenius post-CE, supported by recent funding for commercialization. Leverage existing distributors to enter new markets, while coordinating regulatory and clinical proof points to support multi-country deployments.

Market Need ICU AKI is a widespread and costly problem, with existing practice relying on intermittent, subjective urine checks. Real-time renal diagnostics align with current healthcare trends toward digital health, automation, and data-rich patient monitoring, positioning RenalSense to capture budget-conscious hospital segments.

Partnership Strategy Deepen and expand distribution partnerships and pursue GPO and hospital network deals to drive multi-site adoption. Explore co-marketing and joint procurement initiatives with key distributors and strategic allies (for example, major European distributors via Fresenius) to accelerate scale.